Latest Information Update: 23 Apr 2002
At a glance
- Originator Nonindustrial source
- Mechanism of Action Muscarinic M2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jun 2000 New profile
- 16 Jun 2000 Preclinical development for Alzheimer's disease in England (Unknown route)